What does this research mean for the field?

In previously treated metastatic breast cancer, mitoxantrone is marginally less active than doxorubicin but causes significantly less severe toxicity, including nausea, stomatitis, alopecia, and cardiotoxicity. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 1, 1989Journal of Clinical Oncology

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.

View Full Paper

Ask AI

Bookmark

Why the study?

Does mitoxantrone improve response rate, survival, and toxicity compared to doxorubicin in women with previously treated metastatic breast cancer?

Structured PICO

Does mitoxantrone improve response rate, survival, and toxicity compared to doxorubicin in women with previously treated metastatic breast cancer?

Population

325 women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease

Intervention

Mitoxantrone 14 mg/m2 intravenously (IV) every 3 weeks

Comparator

Doxorubicin 75 mg/m2 intravenously (IV) every 3 weeks

Outcome

Response rate, duration of response, time to progression or death, time to treatment failure (TTF), and survival

Mitoxantrone provides similar survival to doxorubicin in previously treated metastatic breast cancer but with significantly less toxicity, including cardiotoxicity.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Mitoxantrone matches doxorubicin survival with less cardiotoxicity; supports its use as a safer option and informs anthracycline selection in metastatic breast cancer.

Cite This Study

Henderson et al. (1989) studied this question.

synapsesocial.com/papers/6a1bcd3c6f692abb725ee57b https://doi.org/10.1200/jco.1989.7.5.560

View Full Paper

Ask AI

Bookmark

Implication

Mitoxantrone matches doxorubicin survival with less cardiotoxicity; supports its use as a safer option and informs anthracycline selection in metastatic breast cancer.

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.

Structured PICO

Discussion

Implication

Cite This Study

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider